Top

Published in:

01-04-2018 | Brief Report

Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?

Authors: Steven A. John, Thomas H. F. Whitfield, H. Jonathon Rendina, Jeffrey T. Parsons, Christian Grov

Published in: AIDS and Behavior | Issue 4/2018

Abstract

Oral pre-exposure prophylaxis (PrEP) is highly effective at reducing HIV transmission risk and is CDC recommended for many gay, bisexual, and other men who have sex with men (GBM). We sought to investigate awareness of and preference for using long-acting injectable PrEP (LAI-PrEP) among GBM currently taking oral PrEP (n = 104), and identify their concerns. About half of GBM had heard of LAI-PrEP, and 30.8% specifically preferred LAI-PrEP. GBM with more concerns about the level of protection and drug half-life of LAI-PrEP had lower odds of preferring LAI-PrEP. Given that daily pill adherence is a challenge for some on PrEP, it is important to investigate the degree to which those on PrEP might consider LAI-PrEP as an alternative.

CDC. HIV surveillance report, 2015, vol. 27. 2016. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

USFDA. FDA approves first medication to reduce HIV risk. 2012. http://www.fda.gov/forconsumers/consumerupdates/ucm311821.htm.

CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States 2014. A clinical practice guideline. 2014. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf.

Lieb S, Thompson DR, Misra S, et al. Estimating populations of men who have sex with men in the southern United States. J Urban Health. 2009;86(6):887–901.CrossRefPubMedPubMedCentral

Parsons JT, Rendina HJ, Lassiter JM, Whitfield THF, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States: the Motivational PrEP Cascade. J Acquir Immune Defic Syndr. 2017;74(3):285–92.CrossRefPubMedPubMedCentral

Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K. Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States (2013-2015). In: 21st international AIDS conference, Durban, Africa. 2016.

Buchbinder S, Liu A. CROI 2016: hot spots in HIV infection and advances in HIV prevention. Top Antivir Med. 2016;24(1):10–28.PubMed

Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.CrossRefPubMedPubMedCentral

Roberts ST, Heffron R, Ngure K, et al. Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. AIDS Behav. 2014;18(9):1701–11.CrossRefPubMedPubMedCentral

10.

Greene GJ, Swann G, Fought AJ, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2016;21(5):1336–49.CrossRef

11.

Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the US. AIDS Behav. 2016;20(7):1390–9.CrossRefPubMedPubMedCentral

12.

Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.CrossRefPubMedPubMedCentral

Title: Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
Authors: Steven A. John
Thomas H. F. Whitfield
H. Jonathon Rendina
Jeffrey T. Parsons
Christian Grov
Publication date: 01-04-2018
Publisher: Springer US
Published in: AIDS and Behavior / Issue 4/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-017-1907-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

A Study of the Longitudinal Patterns of Stimulant and Amyl Nitrite Use and Sexual Behavior Pre- and Post-HIV Seroconversion Among MSM

Association of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men

Regular Marijuana Use is Associated with Poor Viral Suppression in HIV-Infected Adolescents and Young Adults

Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data

Evaluations of Structural Interventions for HIV Prevention: A Review of Approaches and Methods

Prescription Opioid Use is Associated with Virologic Failure in People Living with HIV

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page